Back to the Disease Index
Psychiatry: Obsessive Compulsive Disorder
Results 1 to 1 of 1 articles.
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008 (Issue 1289)
Fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI) that has been available for many years in an immediate-release formulation (Luvox, and others) for treatment of obsessive-compulsive disorder (OCD) in children and adults, has now been approved by the FDA in an extended-release formulation (Luvox CR - Jazz Pharmaceuticals) for treatment of OCD and social anxiety disorder (SAD) in adults.